Part I: Financial Information [Item 1. Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Consolidated%20Financial%20Statements%20(unaudited)) Unaudited Q1 2025 consolidated financial statements show increased revenue, a larger net loss, reduced cash and equity, and improved operating cash flow [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets slightly decreased, total liabilities increased, and total stockholders' equity significantly declined Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $10,601 | $12,217 | ($1,616) | | Inventories, net | $9,812 | $8,331 | $1,481 | | Total assets | $45,705 | $46,724 | ($1,019) | | Accounts payable | $6,544 | $5,668 | $876 | | Deferred revenue (current) | $8,163 | $6,804 | $1,359 | | Total liabilities | $37,529 | $35,292 | $2,237 | | Total stockholders' equity | $2,880 | $6,080 | ($3,200) | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 operations show increased revenue driven by disposables, but higher costs and expenses resulted in a widened operating and net loss Consolidated Statement of Operations Summary (in thousands) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $7,472 | $6,880 | +8.6% | | Gross Margin | $4,064 | $3,966 | +2.5% | | Total Operating Expenses | $9,993 | $8,712 | +14.7% | | Operating Loss | ($5,929) | ($4,746) | +24.9% | | Net Loss | ($5,823) | ($4,507) | +29.2% | | Net Loss per Share (Basic & Diluted) | ($0.07) | ($0.06) | - | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 cash flows show improved operating cash usage due to working capital, no investing activities, minimal financing, and an overall decrease in cash balances Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,779) | ($2,346) | | Net cash provided by (used in) investing activities | $0 | $0 | | Net cash provided by financing activities | $32 | $30 | | **Net decrease in cash** | **($1,747)** | **($2,316)** | | Cash at end of period | $10,689 | $18,246 | [Notes to Financial Statements](index=8&type=section&id=Notes%20to%20Financial%20Statements) The notes detail business operations, the APT acquisition, significant accounting policies, and key risks, highlighting the company's substantial accumulated deficit - The company designs, manufactures, and markets robotic systems (Robotic Magnetic Navigation) for endovascular interventions, primarily focusing on cardiac ablation procedures for arrhythmias[24](index=24&type=chunk)[25](index=25&type=chunk) - On July 31, 2024, the company acquired Access Point Technologies EP, Inc. (APT) to gain in-house catheter development and manufacturing capabilities, involving upfront stock and contingent payments up to **$24.0 million** based on milestones[35](index=35&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) - The company obtained CE marking for its MAGiC catheter in Europe in Q1 2025 and is pursuing approvals in the U.S. and other regions, while the GenesisX RMN System also has CE Mark and awaits FDA clearance[38](index=38&type=chunk)[151](index=151&type=chunk) - The company faces risks from new tariffs on imports from Mexico, Canada, and China, which could increase costs, alongside ongoing supply chain disruptions, inflation, and logistics delays[42](index=42&type=chunk)[44](index=44&type=chunk)[47](index=47&type=chunk) - As of March 31, 2025, the company has an accumulated deficit of approximately **$567.5 million**, with management believing existing cash is sufficient for the next twelve months but acknowledging the potential need for additional financing[52](index=52&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 revenue growth driven by acquisition, declining gross margin, increased operating expenses leading to higher net loss, and liquidity amidst external risks [Results of Operations](index=36&type=section&id=Results%20of%20Operations) Q1 2025 results show revenue growth from disposables offsetting systems decline, a decrease in gross margin percentage, and a significant increase in total operating expenses Revenue and Gross Margin Comparison (in millions) | Category | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Systems Revenue | $2.0 | $2.6 | -23.1% | | Disposables, Service & Accessories Revenue | $5.5 | $4.3 | +29.0% | | **Total Revenue** | **$7.5** | **$6.9** | **+9.0%** | | **Gross Margin** | **$4.1 (54%)** | **$4.0 (58%)** | **+2.5%** | Operating Expense Comparison (in millions) | Category | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $2.3 | $2.2 | +5.0% | | Sales & Marketing | $3.1 | $3.0 | +5.0% | | General & Administrative | $4.5 | $3.5 | +30.0% | | **Total Operating Expenses** | **$9.9** | **$8.7** | **+14.7%** | [Liquidity and Capital Resources](index=38&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company maintains **$10.7 million** in cash and **$1.7 million** in working capital with no debt, believing current liquidity is sufficient for the next year despite historical losses Liquidity Position (in millions) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents (incl. restricted) | $10.7 | $12.4 | | Working Capital | $1.7 | $4.8 | - Net cash used in operating activities decreased to **$1.8 million** in Q1 2025 from **$2.3 million** in Q1 2024, driven by changes in working capital[190](index=190&type=chunk) - The company has no debt as of March 31, 2025[193](index=193&type=chunk) [Critical Accounting Policies and Estimates](index=34&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) This section details critical accounting policies requiring significant judgment, primarily focusing on revenue recognition for multi-element contracts and stock-based compensation valuation - Revenue from contracts with multiple performance obligations is allocated based on relative standalone selling prices, which may be estimated if not directly observable[171](index=171&type=chunk) - Stock-based compensation expense is determined using valuation models (Black-Scholes for time-based, Monte Carlo for market-based awards) and is amortized over the vesting period[180](index=180&type=chunk)[181](index=181&type=chunk) [Item 4. Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of March 31, 2025, with no material changes to internal controls, while integrating controls of the acquired business - The CEO and CFO concluded that disclosure controls and procedures were effective as of the end of the quarter[196](index=196&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[197](index=197&type=chunk) - The company is currently reviewing and integrating the internal control structure of the acquired business, Access Point Technologies EP, Inc[198](index=198&type=chunk) Part II: Other Information [Item 1. Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings, noting a contested minor vendor dispute regarding a **$0.6 million** UCC financing statement - The company states there are no material legal proceedings[200](index=200&type=chunk) - A vendor filed a UCC financing statement on inventory for approximately **$0.6 million**, which the company is fully contesting[130](index=130&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) This section formally states 'None,' indicating no new or materially changed risk factors are reported here compared to the prior annual filing - The report formally states 'None' for this item, meaning no new risk factors are disclosed in this section[201](index=201&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities[202](index=202&type=chunk) [Item 6. Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents, CEO and CFO certifications, and XBRL data files - The filing includes certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[209](index=209&type=chunk) - Corporate governance documents and Inline XBRL files are included as exhibits[206](index=206&type=chunk)[209](index=209&type=chunk)

Group 1: Financial Performance - Stereotaxis Inc. reported a quarterly loss of $0.07 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.06 per share a year ago [1] - The company posted revenues of $7.47 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.74%, and up from $6.88 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $7.95 million, and for the current fiscal year, it is -$0.26 on revenues of $34 million [7] Group 2: Market Performance and Outlook - Stereotaxis shares have declined approximately 6.6% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The estimate revisions trend for Stereotaxis is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Group 3: Comparative Analysis - Another company in the same industry, Lucid Diagnostics Inc., is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +57.1%, with revenues anticipated to be $1.3 million, up 30% from the previous year [9][10]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 totaled $7.5 million, a 9% increase from $6.9 million in Q1 2024 [21] - System revenue was $2 million, while recurring revenue was $5.5 million compared to $2.6 million and $4.3 million in the prior year [21] - Gross margin for Q1 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [22] - Operating loss and net loss for Q1 2025 were $5.9 million and $5.8 million, respectively, compared to $4.7 million and $4.5 million in the previous year [23] Business Line Data and Key Metrics Changes - MAPIT sales exceeded $1 million in Q1, with a 30% sequential growth in the U.S. market [5] - The MAGIC catheter received European approval, with initial sales expected to generate a couple hundred thousand dollars this quarter, projected to reach approximately $1 million per quarter by the end of the year [9] - Genesis X had its first purchase order in Q1, with expectations for a full launch in Europe and the U.S. following initial commercial use [12] Market Data and Key Metrics Changes - The U.S. market remains challenging due to the lack of MAGIC approval, while Europe shows a more robust pipeline for both Genesis and Genesis X [36] - In China, regulatory approval for Genesis was received, but macroeconomic uncertainties may impact hospital purchases [27] Company Strategy and Development Direction - The company is focusing on growing recurring revenue through its MAPIT portfolio and expanding the adoption of the MAGIC catheter and Genesis X [4][10] - A comprehensive innovation strategy is in place, with six active regulatory reviews and additional products expected to submit for approval soon [14][19] - The goal is to transition from a small installed base of robots to a larger one, enhancing the overall growth potential [62] Management's Comments on Operating Environment and Future Outlook - Management expects double-digit revenue growth for the full year 2025, with system revenue fluctuating between $2 million to $3 million per quarter [26] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue and stable operating expenses [28] - Management remains optimistic about the potential for growth in the Chinese market, viewing it as an upside opportunity [27] Other Important Information - The company is working on enhancing compatibility of Genesis X with various x-ray systems and preparing for a full commercial launch [12] - There are ongoing efforts to finalize regulatory submissions for additional products, including the Synchrony Cath Lab technology and a robotically steered vascular guidewire [19] Q&A Session Summary Question: Can you provide insights on the backlog for Genesis and Genesis X systems? - Management indicated that the capital equipment environment varies by geography, with the U.S. being more challenging until MAGIC and Genesis X are approved [34][36] Question: What feedback has been received from European customers using the MAGIC catheter? - The reception has been positive, with usage across a spectrum of procedures, and management expects a gradual ramp-up in adoption [41][43] Question: What is the timeline for full conversion to MAGIC in the U.S. and Europe? - Management expects a full conversion to occur over approximately two years, with Europe likely seeing substantial adoption by 2026 [59] Question: Are alternative financing models being considered for Genesis X? - Discussions are ongoing regarding various financial models, including leasing and placement, but the focus remains on sales for now [61][62]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 totaled $7.5 million, a 9% increase from $6.9 million in Q1 2024 [20] - System revenue was $2 million, while recurring revenue was $5.5 million, compared to $2.6 million and $4.3 million in the prior year [20] - Gross margin for Q1 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [21] - Operating loss and net loss for Q1 2025 were $5.9 million and $5.8 million, respectively, compared to $4.7 million and $4.5 million in the previous year [22] Business Line Data and Key Metrics Changes - MAPIT sales exceeded $1 million in Q1, with a 30% sequential growth from Q4 [5] - The MAGIC catheter received European approval, with initial sales expected to generate a couple hundred thousand dollars this quarter, projected to reach approximately $1 million per quarter by the end of the year [8][24] - Genesis X had its first purchase order in Q1, with expectations for steady orders in the coming quarters [11][12] Market Data and Key Metrics Changes - The U.S. market remains challenging due to the lack of MAGIC approval, impacting capital equipment purchases [33] - In Europe, there is a more robust pipeline for both Genesis and Genesis X, with ongoing interest from hospitals [36] - The Chinese market presents uncertainty due to macroeconomic conditions, although there is potential upside following recent regulatory approval [25] Company Strategy and Development Direction - The company is focused on growing recurring revenue through its MAPIT portfolio and expanding the adoption of the MAGIC catheter and Genesis X [4][7] - A comprehensive innovation strategy is in place, with multiple regulatory reviews ongoing for key products [13] - The goal is to transition into a company with a significant installed base of robotic systems, enhancing the overall market presence [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, with expectations for double-digit revenue growth in 2025 [24] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue [26] - Management highlighted the importance of regulatory approvals for future growth, particularly for MAGIC and Genesis X [15][16] Other Important Information - The company is working on enhancing compatibility of Genesis X with various x-ray systems and preparing for a full launch in the U.S. and Europe [11] - There are ongoing efforts to finalize regulatory submissions for additional products, including the Synchrony Cath Lab technology [18] Q&A Session Summary Question: Can you provide insights on the backlog for Genesis and Genesis X systems? - Management indicated that the capital equipment environment is challenging in the U.S. due to pending approvals, but there is ongoing interest from hospitals [30][33] Question: What feedback has been received from European customers using the MAGIC catheter? - The reception has been positive, with usage across a spectrum of procedures, and management expects scaling to a $1 million run rate by the end of the year [40][42] Question: How are ordering patterns for the MAGIC catheter among active users? - Initial orders typically consist of small quantities, with hospitals gradually increasing usage as they gain confidence [46][48] Question: What is the status of the MAGIC submission process with the FDA? - The FDA is actively reviewing the submission, and management is addressing detailed questions while compiling clinical data from ongoing studies [50][52] Question: What are the plans for financing options for Genesis X systems? - Discussions are ongoing regarding various financing models, including leasing and placement, to facilitate adoption once the product is approved [60][62]

[Management Commentary & Business Update](index=1&type=section&id=Management%20Commentary%20%26%20Business%20Update) Q1 2025 execution showed recurring revenue growth, MAGiC European launch, and initial GenesisX orders, positioning for 2026 growth - Key Q1 commercial advances include **growth in recurring revenue**, initial **MAGiC catheter commercialization in Europe**, successful **GenesisX robot demonstrations**, and the **first GenesisX system order** along with an additional Genesis system order[3](index=3&type=chunk) - **Six regulatory reviews are ongoing**, with timelines consistent with previous expectations[3](index=3&type=chunk) - Strategic transformation focuses on an easily adopted robotic system with proprietary catheters, projected to drive **breakout growth in 2026**[3](index=3&type=chunk) [Q1 2025 Financial Performance](index=1&type=section&id=Q1%202025%20Financial%20Performance) Q1 2025 total revenue increased 9% to $7.5 million, driven by 29% recurring revenue growth, with net loss widening to $5.8 million due to higher expenses and lower gross margins Q1 2025 Key Financial Metrics (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $7.5M | $6.9M | +9% | | System Revenue | $2.0M | $2.6M | -23% | | Recurring Revenue | $5.5M | $4.3M | +29% | | Gross Margin | 54% | 58% | -4 p.p. | | Operating Loss | ($5.9)M | ($4.7)M | +25% | | Net Loss | ($5.8)M | ($4.5)M | +29% | | Adjusted Operating Loss* | ($2.7)M | ($2.2)M | +23% | | Negative Free Cash Flow | ($1.8)M | ($2.3)M | -22% | *Excludes non-cash charges - Gross margins were impacted by **acquisition-related accounting** and **fixed overhead allocation over low system production levels**[5](index=5&type=chunk) - Operating expenses increased to **$10.0 million** (or **$6.8 million adjusted**), primarily due to **Access Point Technologies operations**[6](index=6&type=chunk) [Financial Position and Liquidity](index=2&type=section&id=Financial%20Position%20and%20Liquidity) As of March 31, 2025, Stereotaxis maintained a debt-free balance sheet with **$10.7 million** in cash and equivalents Cash and Debt Position | Metric | As of March 31, 2025 ($ million) | | :--- | :--- | | Cash and Cash Equivalents | $10.7 | | Debt | $0 | [2025 Full Year Outlook](index=2&type=section&id=2025%20Full%20Year%20Outlook) Stereotaxis expects **double-digit revenue growth** for 2025, with **$2-3 million** quarterly system revenue and **$7 million** recurring revenue by Q4, anticipating reduced cash usage - Stereotaxis expects **double-digit revenue growth** for the full year 2025[9](index=9&type=chunk) - Guidance assumes **$2-3 million** system revenue per quarter and recurring revenue scaling to **$7 million in Q4 2025**, with modest GenesisX Europe contributions and no China system revenue[9](index=9&type=chunk) - The company expects **reduced cash use in 2025** compared to 2024, supported by growing recurring revenue and stable operating expenses[10](index=10&type=chunk) [Consolidated Financial Statements](index=3&type=section&id=Consolidated%20Financial%20Statements) Unaudited consolidated financial statements detail a **$5.8 million net loss** for Q1 2025, with total assets of **$45.7 million** and total liabilities of **$37.5 million** as of March 31, 2025 [Consolidated Statements of Operations](index=3&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 Statement of Operations (Unaudited, in thousands) | | Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2025** | **2024** | | **Total revenue** | **$7,472** | **$6,880** | | Gross margin | $4,064 | $3,966 | | Total operating expenses | $9,993 | $8,712 | | **Operating loss** | **($5,929)** | **($4,746)** | | Interest income, net | $106 | $239 | | **Net loss** | **($5,823)** | **($4,507)** | | Net loss per share (Basic & Diluted) | ($0.07) | ($0.06) | [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Consolidated Balance Sheet Highlights (Unaudited, in thousands) | | **March 31, 2025** | **December 31, 2024** | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | $10,601 | $12,217 | | Inventories, net | $9,812 | $8,331 | | **Total Assets** | **$45,705** | **$46,724** | | **Current Liabilities** | | | | Accounts payable | $6,544 | $5,668 | | Deferred revenue | $8,163 | $6,804 | | **Total Liabilities** | **$37,529** | **$35,292** | | **Total Stockholders' Equity** | **$2,880** | **$6,080** |

Core Insights - Stereotaxis reported a 9% increase in revenue for Q1 2025, totaling $7.5 million compared to $6.9 million in Q1 2024, driven by a 29% growth in recurring revenue [3][8] - The company is focused on advancing its innovation strategy, with key commercial advances including the initial commercialization of MAGiC in Europe and successful demonstrations of the GenesisX robot [2][8] - Stereotaxis expects double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue scaling to $7 million in Q4 2025 [8][9] Financial Performance - System revenue for Q1 2025 was $2.0 million, down from $2.6 million in Q1 2024, while recurring revenue reached $5.5 million, up from $4.3 million [3][13] - Gross margin for Q1 2025 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [4][14] - Operating loss for Q1 2025 was ($5.9) million, compared to ($4.7) million in Q1 2024, with adjusted operating loss at ($2.7) million [6][14] Cash and Liquidity - As of March 31, 2025, Stereotaxis had cash and cash equivalents of $10.7 million and no debt [7][15] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue and stable operating expenses [9] Regulatory and Market Outlook - Stereotaxis is advancing multiple regulatory efforts with six active reviews and plans for additional submissions, aiming for significant adoption of GenesisX pending regulatory approval in the U.S. [2][8] - The company expects substantial growth in 2026, supported by anticipated regulatory milestones and initial commercial launches in 2025 [8]

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. About Stereotaxis Stereotaxis (NYSE: STXS) is a pion ...

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating ...

Industry Overview - The surgical robotics market is experiencing rapid growth, driven by advances in minimally invasive surgery, with a market value of $11.48 billion in 2024 and a projected compound annual growth rate of 12.4% from 2025 to 2030 [2] - Key growth drivers include the integration of AI, which enhances precision and reduces complications, and the increasing demand for robotic surgeries due to an aging global population [6][7] Major Areas of Growth - Minimally invasive surgery is a significant factor driving the adoption of surgical robotics, providing benefits such as precision, smaller incisions, and faster recovery times across various fields including urology, gynecology, orthopedics, and general surgery [5] - The aging population is increasing the demand for robotic surgery systems, as these systems offer improved precision and lower risks for older patients [7] Company Analysis Intuitive Surgical - Intuitive Surgical's da Vinci surgical system has been a key performance driver since its launch, offering minimally invasive surgery and supporting rapid adoption through an integrated ecosystem [9] - The company has a long-term expected EPS growth rate of 16.1%, with projected revenue growth of 14.4% for 2025 [10] Zimmer Biomet - Zimmer Biomet is focusing on expanding its ROSA Robotics portfolio, which includes systems for knee, hip, and shoulder surgeries, enhancing the surgical experience [11][12] - The company has a projected sales growth rate of 2.6% for 2025, with a favorable current cash flow rate of 3.6% [13] Stereotaxis - Stereotaxis is expanding its global presence and has achieved regulatory approvals for its next-generation robotic system, GenesisX, enhancing its competitive position [14] - The company has a projected sales growth rate of 26.3% for 2025, with a favorable current cash flow rate of 13.1% [15]

Core Insights - Stereotaxis has been recognized by NVIDIA at the GTC conference and accepted into the NVIDIA Connect program, which will enhance its technological capabilities in surgical robotics [1][2]. Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, with its technology used in over 100 hospitals globally, treating more than 150,000 patients [3][4]. - The company is focusing on advancing its robotic systems through digital solutions that incorporate AI, robotic automation, data integration, and decision support capabilities [3]. Industry Context - The NVIDIA GTC conference, attended by over 25,000 participants, emphasizes the integration of AI in various applications, including healthcare and surgical robotics [2]. - The collaboration with NVIDIA is expected to significantly enhance the precision, safety, and stability of Stereotaxis' robotic systems, potentially transforming patient treatment [4].